The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome
- PMID: 16948861
- PMCID: PMC1570348
- DOI: 10.1186/1476-511X-5-24
The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome
Abstract
Aim: Once considered a problem of developed countries, obesity and obesity-related complications (such as metabolic syndrome) are rapidly spreading around the globe. The purpose of the present study was to investigate the use of a Cissus quadrangularis formulation in the management of metabolic syndrome, particularly weight loss and central obesity.
Methods: The study was a randomized, double-blind, placebo-controlled design involving 123 overweight and obese persons (47.2% male; 52.8% female; ages 19-50). The 92 obese (BMI >30) participants were randomized into three groups; placebo, formulation/no diet, and formulation/diet (2100-2200 calories/day). The 31 overweight participants (BMI = 25-29) formed a fourth (no diet) treatment group. All participants received two daily doses of the formulation or placebo and remained on a normal or calorie-controlled diet for 8 weeks.
Results: At the end of the trial period, statistically significant net reductions in weight and central obesity, as well as in fasting blood glucose, total cholesterol, LDL-cholesterol, triglycerides, and C-reactive protein were observed in participants who received the formulation, regardless of diet.
Conclusion: Cissus quadrangularis formulation appears to be useful in the management of weight loss and metabolic syndrome.
Similar articles
-
The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress.Lipids Health Dis. 2007 Feb 4;6:4. doi: 10.1186/1476-511X-6-4. Lipids Health Dis. 2007. PMID: 17274828 Free PMC article. Clinical Trial.
-
The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study.Lipids Health Dis. 2008 Mar 31;7:12. doi: 10.1186/1476-511X-7-12. Lipids Health Dis. 2008. PMID: 18377661 Free PMC article. Clinical Trial.
-
The Use of Cissus quadrangularis (CQR-300) in the Management of Components of Metabolic Syndrome in Overweight and Obese Participants.Nat Prod Commun. 2015 Jul;10(7):1281-6. Nat Prod Commun. 2015. PMID: 26411031 Clinical Trial.
-
A review and evaluation of the efficacy and safety of Cissus quadrangularis extracts.Phytother Res. 2013 Aug;27(8):1107-14. doi: 10.1002/ptr.4846. Epub 2012 Sep 13. Phytother Res. 2013. PMID: 22976133 Review.
-
Role of Cissus quadrangularis in the Management of Osteoporosis: An Overview.Crit Rev Ther Drug Carrier Syst. 2021;38(5):27-51. doi: 10.1615/CritRevTherDrugCarrierSyst.2021033808. Crit Rev Ther Drug Carrier Syst. 2021. PMID: 34375512 Review.
Cited by
-
The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress.Lipids Health Dis. 2007 Feb 4;6:4. doi: 10.1186/1476-511X-6-4. Lipids Health Dis. 2007. PMID: 17274828 Free PMC article. Clinical Trial.
-
Effect of Myristica fragrans extract on total body composition in cafeteria diet induced obese rats.Bioinformation. 2019 Oct 13;15(9):657-665. doi: 10.6026/97320630015657. eCollection 2019. Bioinformation. 2019. PMID: 31787815 Free PMC article.
-
Depletion of β-sitosterol and enrichment of quercetin and rutin in Cissus quadrangularis Linn fraction enhanced osteogenic but reduced osteoclastogenic marker expression.BMC Complement Med Ther. 2020 Apr 3;20(1):105. doi: 10.1186/s12906-020-02892-w. BMC Complement Med Ther. 2020. PMID: 32245457 Free PMC article.
-
Evaluation of the anti-osteoarthritic effects and mechanisms of Cissus quadrangularis extract containing quercetin and isorhamnetin in a rat model of monosodium iodoacetate-induced osteoarthritis.Food Nutr Res. 2025 Apr 15;69. doi: 10.29219/fnr.v69.12173. eCollection 2025. Food Nutr Res. 2025. PMID: 40264489 Free PMC article.
-
The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study.Lipids Health Dis. 2008 Mar 31;7:12. doi: 10.1186/1476-511X-7-12. Lipids Health Dis. 2008. PMID: 18377661 Free PMC article. Clinical Trial.
References
-
- Grundy SM, Brewer HB, Jr, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438. doi: 10.1161/01.CIR.0000111245.75752.C6. - DOI - PubMed
-
- Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon M, Heymsfield S. The metabolic syndrome prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163:427–36. doi: 10.1001/archinte.163.4.427. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials